Pfizer Announces $4.9 Billion Acquisition of Obesity Drug Developer Metsera

In a strategic move to expand its presence in the rapidly growing market for obesity treatment, pharmaceutical giant Pfizer has agreed to acquire Metsera, a company specializing in medications for obesity and cardiovascular conditions, for $4.9 billion. This acquisition aims to position Pfizer as a key player in the lucrative obesity and related health condition sectors.

The deal, which involves Pfizer purchasing all outstanding shares of Metsera at $47.50 per share, is anticipated to close in the final quarter of 2025. The move follows a broader industry trend where major pharmaceutical companies are investing heavily in obesity and diabetes therapeutics, motivated by the success of drugs like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound.

Pfizer CEO Albert Bourla highlighted the strategic importance of this investment, stating that obesity is a substantial and expanding health issue with over 200 associated conditions. He emphasized that the acquisition aligns with Pfizer’s goal to focus on impactful therapeutic areas.

This acquisition also comes at a time when Pfizer’s stock has faced fluctuations since the end of the COVID-19 pandemic, with its share price dropping from $58 in December 2021 to around $24 recently. Notably, in pre-market trading on Monday, Pfizer's stock rose by 1.6%, while Metsera's shares surged by 60%, indicating strong investor optimism.

The move marks Pfizer’s entrance into a highly competitive market, where the demand for effective obesity treatments continues to grow, driven by increasing global health concerns. Industry experts observe that Pfizer's entry could intensify competition and innovation in this segment.

For more details, visit source: https://medicalxpress.com/news/2025-09-pfizer-obesity-drug-maker-metsera.html